You are here

Better Health Literacy Seems To Boost Patient Satisfaction With Biosimilars

European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.

European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.

There seems to be a relationship between a patient’s willingness to switch to a biosimilar and health literacy, according to study presented by Milada Cvancarova Smastuen and colleagues at the European League Against Rheumatism’s Annual European Congress of Rheumatology in June in Amsterdam. About one in five patients taking etanercept (Enbrel) or infliximab (Remicade) who were switched to less expensive biosimilars said that they were dissatisfied. But the study adds that the patients’ level of satisfaction with the switch was associated with health literacy, which researchers defined as being given sufficient and necessary information about their health.

Source: Center for Biosimilars

More Headlines

Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
A meta-analysis that included 18 million participants found no protection from heart disease or stroke.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.
Some of that can be chalked up to the differences in cost of living from place to place, but not all.
Health plans expected to continue pushing for value-based payment arrangements.
One of the proposed changes makes remote patient monitoring an allowable cost.
Puts down $700 million to buy nearly 50% of Samsung.
The move comes even though some of the pharma company’s rivals have promised to raise prices only once a year.